Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Paltiel

Dermatology Forest Hills, NY Medical Doctor

NPI 1760525935 CMS profile 171148

6405 Yellowstone Blvd, Cfu 101, Forest Hills, NY 11375

Open in the dashboard

General payments

$13,350

623 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$9,209 paid to institutions, not to them · program year 2019

Through program year 2025, Michael Paltiel of Forest Hills, NY is reported in the CMS Open Payments database as having received $13,350 across 623 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $9,209 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,092 99
2024 General $2,026 95
2023 General $1,898 81
2022 General $1,837 95
2021 General $2,705 106
2020 General $1,322 65
2019 General $1,470 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Paltiel
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Michael Paltiel were reported at $2,092. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Michael Paltiel Dermatology median Middle half National median
2019 $1,470 $454 $129–$1,240 $163
2020 $1,322 $235 $81–$756 $114
2021 $2,705 $377 $108–$1,108 $132
2022 $1,837 $514 $143–$1,391 $149
2023 $1,898 $607 $159–$1,674 $160
2024 $2,026 $751 $204–$1,903 $164
2025 $2,092 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,164 110 payments
  2. Pfizer Inc. $1,030 53 payments
  3. Lilly USA, LLC $1,020 45 payments
  4. Genzyme Corporation $993 37 payments
  5. Sun Pharmaceutical Industries Inc. $963 59 payments
  6. Janssen Biotech, Inc. $920 43 payments
  7. Merz North America, Inc. $779 6 payments
  8. Amgen Inc. $536 21 payments
  9. Arcutis Biotherapeutics, Inc. $533 31 payments
  10. Novartis Pharmaceuticals Corporation $471 27 payments
  11. Other $3,942 191 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,186 619 payments
  2. Education $164 4 payments
Products named General payments · program years 2019–2025
  1. SKYRIZI $1,236 65 payments
  2. TALTZ $891 40 payments
  3. EUCRISA $823 43 payments
  4. TREMFYA $815 39 payments
  5. DUPIXENT $810 28 payments
  6. Xeomin $750 4 payments
  7. ILUMYA $677 41 payments
  8. CIBINQO $585 28 payments
  9. VTAMA $541 21 payments
  10. Otezla $514 20 payments
  11. Other $6,171 316 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,645

Median for Dermatology: 534

Drug cost

$266,923

Median for Dermatology: $67,151

Branded share of claims

11.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 23 $110,454
Opzelura Ruxolitinib Phosphate Brand 30 $59,385
Jublia Efinaconazole Brand 25 $33,490
Ketoconazole Generic 387 $13,347
Zoryve Roflumilast Brand 14 $11,705
Tacrolimus Generic 60 $9,062
Metronidazole Generic 193 $8,746
Triamcinolone Acetonide Generic 167 $5,504
Halobetasol Propionate Generic 88 $3,836
Clobetasol Propionate Generic 81 $3,005

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$420,573

Of which drugs: $80

Medicare patients

917

Average age 76

Services billed

6,578

537 women, 380 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 66%
Diabetes 59%
Ischemic heart disease 49%
Depression 37%
COPD 23%
Chronic kidney disease 22%
Heart failure 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 72 109 $80

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $284
  • Regeneron Healthcare Solutions, Inc. $42
$326 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $292
$292 14 —
VTAMA
  • Dermavant Sciences, Inc. $244
$244 — —
BOTOX
  • AbbVie, Inc. $132
$132 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $99
$99 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

623 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record